The Selective Endothelin Receptor Antagonist SC0062 in IgA Nephropathy

What is it about?

Patients with IgA nephropathy in whom the concentration of urine proteins are increased are at higher risk of kidney failure compared to patients with lower levels of urine proteins. This study demonstrates that a new drug that blocks the activity of endothelin-1 reduces urine proteins in patients with IgA nephropathy and was well tolerated. This study support conduct of future studies to assess the longer term efficacy and safety of this new drug.

Featured Image